Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 57Leukemia 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma 20Congenital Abnormalities 19Prostatic Neoplasms 18Lymphoma, Non-Hodgkin 14Leukemia, Erythroblastic, Acute 14Leukemia, Myelomonocytic, Acute 13Leukemia, Monocytic, Acute 13Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Follicular 12Leukemia, Megakaryoblastic, Acute 12Myelodysplastic Syndromes 10Lymphoma, Large-Cell, Immunoblastic 9Leukemia, Lymphocytic, Chronic, B-Cell 7Recurrence 5Lymphoma, Mantle-Cell 5Breast Neoplasms 5Anemia, Refractory, with Excess of Blasts 5Neoplasms 4Leukemia, Biphenotypic, Acute 4Burkitt Lymphoma 4Blast Crisis 4Ovarian Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Eosinophilic, Acute 3Leukemia, Basophilic, Acute 3Hodgkin Disease 3

Interventions

Mitoxantrone 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Androgen-independent Prostate Cancer × Mitoxantrone × Clear all
NCT00661492 2016-12-09

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

US Oncology Research

Phase 2 Completed
115 enrolled 16 charts
Genitourinary

Androgen-independent Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡